New CEO Commits to Strengthening OMP’s Leadership in Advanced Supply Chain Planning
ANTWERPEN, BELGIUM / ACCESSWIRE / October 29, 2024 / In a leadership transition at the Antwerp-based supply chain specialists, Anita Van Looveren will step into her new role as Chairwoman of the Board of Directors on November 1, after nearly 25 years in the CEO role and almost 40 years with the company. Paul Vanvuchelen, Global Delivery Lead, will succeed her as CEO, beginning a new chapter for OMP with a focus on strengthening its leadership in advanced supply chain planning. In her new position, Anita Van Looveren will continue to work closely with Paul Vanvuchelen, offering strategic guidance and support.
Anita Van Looveren and Paul Vanvuchelen
Under the stewardship of company founder Georges Schepens and long-time CEO Anita Van Looveren, OMP has grown into a global leader inadvanced supply chain planning. Since its inception in 1985, OMP has built a strong reputation by working with an expanding portfolio of customers, including innovative startups and blue-chip giants. OMP has helped them navigate challenging market conditions, geopolitical issues, and, most recently, the worldwide pandemic. Georges Schepens, as outgoing Chair, will remain a member of the Board.
Pioneering advanced supply chain planning
Based in Antwerp, Belgium, OMP employs over 1,200 people worldwide and serves some of the world's most iconic and innovative companies, principally in the life sciences, consumer goods, chemical, metals, and paper, plastics & packaging industries. OMP was recently recognized as a leading force in supply chain planning in the Gartner Magic Quadrant for the ninth successive year. This recognition highlights OMP's ability to deliver tangible results while driving its vision of embedding innovation into future supply chain solutions.
A seasoned leader in the industry
Paul Vanvuchelen takes over at a time when the world's supply chains in every industry are under severe pressure from global events and evolving market conditions. With a longstanding track record as a business leader in the metals industry prior to his work at OMP, Paul Vanvuchelen served as former CEO at Aperam Stainless Belgium and Chief Performance Officer at Aperam Global. He is credited with successfully transforming and optimizing the company's footprint and supply chain, significantly improving costs, inventories, and service levels, through digitalization, automation, and organizational efficiency projects.
After joining OMP in 2013, Paul Vanvuchelen began as metals industry lead before moving to the role of Global Delivery Lead. He is known among colleagues and customers alike for his deep understanding of supply chains and the business acumen required to lead OMP into the next phase of its journey.
Delivering real value in a world of constant change
As he takes up his new role, Paul Vanvuchelen pays tribute to Anita Van Looveren: "It's a great honor to succeed Anita and lead this exciting business. Supply chain planning affects everyone all over the world, and we at OMP help global enterprises get better and better at it every day. It's especially challenging and thrilling in a world of constant change, with new technologies emerging at a rapid pace."
Transitioning to her new role, Anita Van Looveren praises Paul Vanvuchelen's leadership and team spirit: "Paul has been a driving force at OMP for many years, encouraging colleagues to maximize their potential. I'm confident he'll continue to do that in his new role, allowing every individual to bring real value to our customers."
Continuity and stakeholder collaboration
The transition has been carefully planned to have no effect on OMP's shareholder structure. The company's ambition for future growth remains intact, thanks in large to the expertise and dedication of its global teams, who develop, implement, and support OMP's next-generation Unison Planning™ solution.
About OMP
OMP helps companies facing complex planning challenges to excel, grow and thrive by offering the best digitized supply chain planning solution on the market. Hundreds of customers in a wide range of industries - spanning consumer goods, life sciences, chemicals, metals, paper, plastics & packaging - benefit from using OMP's unique Unison Planning™.
Contact Information
Katleen Rybczynski
Senior Communications Manager
krybczynski@omp.com
+32 3 650 23 22
SOURCE: OMP
View the original press release on newswire.com.
OMP
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
“Bogotá Your Home”: A Showcase of Bogotá’s New Image at COP1629.10.2024 14:30:00 CET | Press release
BOGOTÁ, COLOMBIA / ACCESSWIRE / October 29, 2024 / "Bogotá tu casa" - "Bogotá Your Home", a campaign led by the District Institute of Tourism in collaboration with the Bogotá Chamber of Commerce and Invest in Bogotá, was showcased at COP16 to hundreds of visitors. The campaign highlighted the capital's key attributes and opportunities for tourists, entrepreneurs, and investors. "As Invest in Bogotá, we supported this activation to show the world why Bogotá is a city full of opportunities for businesspeople, investors, and global-scale events. We look forward to guiding international decision-makers in exploring the city's investment opportunities as a platform for business expansion and growth", said Isabella Muñoz. "Bogotá Your Home," the new campaign by the Bogotá District Institute of Tourism, the Bogotá Chamber of Commerce, and Invest in Bogotá, was promoted at COP16. The event took place at the House of Bogotá and the Bogotá Chamber of Commerce at Bulevar del Río in Cali, the host
Dr. Falk Pharma Acquires Kynos Therapeutics, Adding Acute Pancreatitis as a Therapeutic Focus and Further Strengthening Its Development Portfolio29.10.2024 08:00:00 CET | Press release
FREIBURG, GERMANY / ACCESSWIRE / October 29, 2024 / Today, Dr. Falk Pharma GmbH announces the successful acquisition of Kynos Therapeutics Ltd., a clinical stage biopharmaceutical company focusing on the development of novel treatments for patients suffering from acute and chronic inflammatory diseases. The company was founded as a spin-out of the University of Edinburgh, Scotland, together with lead investor Epidarex Capital, a leading early-stage transatlantic venture fund, along with IP Group, and Scottish Enterprise. Effective immediately, Kynos Therapeutics will be integrated into the Falk Group. Dr. Falk Pharma Dr. Falk Pharma Logo Kynos Therapeutics' lead investigational asset is KNS366, a highly potent and selective first-in-class inhibitor of the enzyme kynurenine 3-monooxygenase (KMO). In a Phase I clinical trial, KNS366 was shown to be safe and well-tolerated at multiple doses. The compound also led to a dose-dependent inhibition of the enzyme KMO and modulation of its downs
Polaris Renewable Energy Announces Acquisition Transaction in Puerto Rico29.10.2024 07:50:00 CET | Press release
TORONTO, ON / ACCESSWIRE / October 29, 2024 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company"), is pleased to announce that it has entered into an Equity Capital Contribution Agreement ("ECCA") with respect to Punta Lima Wind Farm LLC (a wholly owned subsidiary of Santander Bank N.A. -"Santander"-). The project is an operating onshore wind farm called Punta Lima Wind Farm ("PLWF" or the "Project") with a nameplate capacity of 26.0 MW's located in the Municipality of Naguabo, Puerto Rico. The Project was re-constructed and recommissioned by Santander and has a 20-year power purchase agreement ("PPA") in place with Puerto Rico Electric Power Authority (PREPA) terminating in March 2044. The transaction is being completed using a tax-equity structure which will result in Polaris becoming the manager and operator of the Project with a controlling equity interest and Santander retaining a tax equity interest in the Project. the transaction is subject to customary closing
BioNxt Announces National Level Patent Filings for Sublingual Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases29.10.2024 03:05:00 CET | Press release
VANCOUVER, BC / ACCESSWIRE / October 29, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased to announce that it has initiated the nationalization process for the filing of a family of patents for the sublingual delivery of anticancer drugs for the treatment of autoimmune neurodegenerative diseases. The patents are 100% owned by BioNxt. Subject to the international Patent Cooperation Treaty ("PCT"), the European Patent Office ("EPO") issued a positive International Preliminary Report on Patentability ("IPRP"), announced by the Company on September 9, 2024. The EPO accepted the Company's claim that the patent family was new, useful, and non-obvious, satisfying the requirements for patentability. Based on the report's findings, BioNxt is advancing its patent protection process to national level filings in the following international jurisdictions: Independent filing nations: Australia (AU), Canada (CA), New Zealand (NZ), USA (US), Japan
Opti Digital Breaks Down the Biggest AdTech Trends in 202528.10.2024 18:39:00 CET | Press release
As the ad tech landscape evolves, 2025 promises to be a pivotal year for digital advertising, with key trends already emerging. BARCELONA, SPAIN / ACCESSWIRE / October 28, 2024 / Magali Quentel-Reme, CEO of Opti Digital; Mohsin Pervez, Senior Director of Platform Solutions and Operations, EMEA at PubMatic; and Langdon Miller, Director of Programmatic at Brainly, share their insights on the future of the AdTech landscape and the key trends set to shape programmatic in 2025. Addressability Solution With over 50% of third-party cookies already phased out and Google's pivotal July 2024 announcement granting users control over cookie settings, the need for effective alternatives is more critical than ever. Langdon Miller, Director of Programmatic at Brainly, explains that " the integration of probabilistic and deterministic IDs, first-party data, contextual segmentation, and bid decoration has led to sustained performance and increased yield. " This is echoed on the buy side, with a growing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom